References
- SalvoMCBrooksADThackerSMPatient considerations in the management of type 2 diabetes – critical appraisal of dapagliflozinPatient Pref Adherence20148493502
- FerranniniERamosSJSalsaliATangWListJFDapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise – a randomized, double-blind, placebo-controlled, phase 2 trialDiabetes Care2010332217222420566676
- JiLMaJLiHDapagliflozin as monotherapy in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III studyClin Ther2014368410024378206
- JabbourSAHardyESuggJParikhSDapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicentre, randomized, double-blind, placebo-controlled studyDiabetes Care20143774075024144654
- WingRRBolinPBrancatiFLLook AHEAD Research GroupCardiovascular effects of intensive lifestyle intervention in type 2 diabetesN Engl J Med201336914515423796131
- MintzMLMinerviniGSaxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemiaCurr Med Res Opin20143076177024397584
- GallwitzBGuzmanJDottaFExenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label randomised controlled trialLancet201237998332270227822683137
- Dapagliflozin (Forxiga)Summary of product characteristicsBristol-Myers SquibbUxbridge, UK2014 Available from: http://www.medicines.org.uk/EMC/medicine/27188Accessed May 26, 2014
- ClinicalTrials.govMulticenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58) Available from: http://clinicaltrials.gov/ct2/show/NCT01730534?term=dapagliflozin&rank=36Accessed May 26, 2014
References
- SalvoMCBrooksADThackerSMPatient considerations in the management of type 2 diabetes – critical appraisal of dapagliflozinPatient Pref Adherence20148493502
- InzucchiSEBergenstalRMBuseJBManagement of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD)Diabetes Care20123561364137922517736
- FerranniniERamosSJSalsaliATangWListJFDapagliflozin in monotherapy in type 2 diabetes patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trialDiabetes Care201033102217222420566676
- KomoroskiBVachharajaniNBoultonDDapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glycosuria in healthy subjectsClin Pharmacol Ther200985552052619129748
- WildingJPNorwoodPT’joenCA study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatmentDiabetes Care20093291656166219528367
- ListJFWooVMoralesETangWFiedorekFTSodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetesDiabetes Care200932465065719114612
- Look AHEAD Research GroupWingRRBolinPCardiovascular effects of intensive lifestyle intervention in type 2 diabetesN Engl J Med201336914515423796131
- US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research: Guidance for IndustryDiabetes Mellitus – Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdfAccessed July 27, 2014